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Early staging classifications for Hodgkin's disease merely
reflected the natural history of the disease since no effective
therapy was available, with Reed describing two stages in
1902 and Longcope and McKalpin seven by 1920. It was not
until considerably later that a classification relevant to a
potentially curative local therapy began to appear (Craver,
1948). In 1950 correlation of presentation features from
patients treated with radiotherapy over a 20-year period at a
single centre led to the evolution of a classification which is
the prototype of that recommended for use today. Peters
(1950) and subsequently Peters & Middlemiss (1958) analysed
the survival patterns of consecutive patients with biopsy pro-
ven Hodgkin's disease treated at the Princess Margaret Hos-
pital, Toronto, between 1924 and 1948, with either local or
extended field radiotherapy. While finding that age, gender
and duration of symptoms before therapy all contributed to
survival, their main conclusion was that the extent of disease
was by far the strongest predictor of survival and survival
without recurrence following radiotherapy. A three stage
classification was proposed with a subdivision of stage II to
accommodate the presence or absence of symptoms. The
simplicity of the classification made it easy to apply but by
the time of the Rye conference in 1966 revision was
indicated, with Kaplan and his colleagues at Stanford Uni-
versity in the United States recommending a fourth stage for
disseminated disease (Kaplan et al., 1964).
The Rye Classification (Rosenberg, 1966) was an improve-
ment on its predecessor in two ways, first by recognising the
subdivision of stage III into stages III and IV and secondly
by laying down specific guidelines for the investigation of the
patient with Hodgkin's disease. Not only did this permit
more meaningful comparison of data from different centres
but the techniques available by this time in themselves per-
mitted an increased precision with which Hodgkin's disease
could be located anatomically. The practical relevance of this
was enhanced by the general, but not complete, acceptance of
the 'orderly spread of Hodgkin's disease' (Rosenberg & Kap-
lan, 1966).
At the Workshop on the staging of Hodgkin's disease at
Ann Arbor, Michigan, in April 1970 an international panel
of medical oncologists, radiotherapists and pathologists
agreed on a staging classification now known as the Ann
Arbor Classification (Carbone et al., 1971). This classification
has provided a rational basis for curative treatment decisions
for almost two decades. In this classification a distinction is
drawn between clinical stage (CS) and pathological stage
(PS). Clinical stage is based on information derived from the
initial biopsy, history, physical examination, laboratory tests,
radiographic examinations and radioisotopic scans. Patho-
logical stage is, in addition, based on macroscopic and micro-
scopic evidence derived from laparotomy or laparoscopy,
splenectomy, liver biopsy, marrow biopsy and/or additional
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lymph node or other tissue biopies - each patient receiving
both a CS and a PS designation. The classification also
introduced the suffix 'E' to denote extra nodal extension
which might be encompassed within the same, curative radia-
tion field as the n'odal site itself (IFIIF).
During the past 20 years new developments have taken
place which have improved our ability to locate disease and
new features of prognostic importance have been recognised.
For patients treated with radiotherapy alone, prognosis cor-
relates not only with stage and the presence of symptoms as
delineated in the Ann Arbor Classification but also with
other factors such as bulk of disease, number of involved
nodal sites and laboratory procedures, which were not men-
tioned or were considered optional in the Ann Arbor report.
New techniques for determining sites of disease, such as
computed tomography, have become available and have been
introduced into routine staging, replacing others recommend-
ed in the Ann Arbor report. For these reasons, a revision of
the Ann Arbor scheme was carried out and modifications
were recommended in the staging procedures within the
framework of the Ann Arbor Classification by a committee
meeting in the Cotswolds under the auspices of the Cancer
Research Campaign and Imperial Cancer Research Fund
(Cotswolds Report: Lister et il., 1989). The committee in-
cluded pathologists, radiologists, radiotherapists and medical
oncologists, with representatives of both specialised referral
centres and major collaborative groups.
There is no evidence that laparotomy with splenectomy
improves survival and the procedure can be associated with
important surgical complications, delay in initiating therapy
and the subsequent risk of fulminating infection associated
with immunodepression. For these reasons oncologists from
many centres have abandoned the use of staging laparotomy
and make treatment decisions based on clinical staging
methods. There is no evidence that this approach is inferior
in terms of overall survival. For these reasons, the emphasis
of the Cotswolds report was on clinical staging.
The criteria for the presence of B symptoms have been
more clearly defined. The fact that abnormal liver function
tests are not necessarily indicative of liver involvement by
Hodgkin's disease has been recognised and clinical enlarge-
ment alone with or without abnormalities of liver function
tests is no longer considered adequate in classifying the liver
as involved. Multiple focal defects which are neither cystic
nor vascular must be identified using at least two imaging
techniques. The clinical criteria for defining an 'E' lesion
(extranodal extension) have been improved but are still not
perfect. The definition of 'limited direct extension from a
adjacent nodal site with the implicit expectation of a prog-
nosis equivalent to that for treatment of nodal disease of the
same anatomical extent' is still vague. There is no clear
dividing line between E, multiple E and stage IV.
Although bipedal abdominal lymphangiography is an ac-
curate diagnostic tool for the assessment of paraortic and
paracaval nodal disease, the technique is poor in evaluating
lymph nodes in the upper abdomen. Coeliac axis nodes are
hardly ever visualised and this is a common site for Hodg-
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kin's disease to be found at staging laparotomy. Portal,
splenic, hilar and mesenteric nodes are never visualised.
Other difficulties include the risk of local infection and
breathlessness associated with lipid microemboli in patients
with large mediastinal masses or extensive retroperitoneal
lymph node involvement. The technique may not be possible
in patients with peripheral oedema. Computed tomography
of the abdomen is helpful in evaluating upper abdominal
nodal disease and can detect enlargement of coeliac portal
and splenic hilar nodes. CT scanning is capable of demon-
strating additional mediastinal adenopathy not detected on
plain radiographs and may show extension into extra nodal
tissues such as lung, pericardium and chest wall. This inform-
ation can be important in planning radiotherapy treatment
fields and deciding whether chemotherapy should be used.
For these reasons CT scanning of the chest, abdomen and
pelvis is recommended and has become routine in the initial
evaluation of Hodgkin's disease (Crowther et al., 1979). Bi-
pedal lymphangiography is being used less often, however the
techniques are complementary and ideally both should be
used to evaluate the patient fully (Castellino et al., 1984).
The recommended pretreatment evaluation procedures in
the Cotswolds report include a number of parameters which
although not directly related to staging are nevertheless of
importance in terms of prognosis and may be taken into
consideration when planning treatment. These include fea-
tures not included in the Ann Arbor report such as perfor-
mance status, age, gender, assessment of mediastinal bulk
(defined as the maximum width equal or greater than one
third of the internal transverse diameter of the thorax at the
level of T5/6) and measurements of serum lactate dehydro-
genase and albumin. Measurements of ESR, total lympho-
cyte count and number of nodal sites of involvement are also
of prognostic importance and are recommended in the initial
evaluation.
An additional problem covered by the Cotswolds report
included the definition of complete remission following the
recognition that residual abnormality of radiology, such as
abnormal widening of the mediastinum, minor abnormalities
of retroperitoneal tissues on CT scanning or architectural
distortion of lymphography, may persist for many years and
may not reflect active disease (Jochelson et al., 1985; Radford
et al., 1988). A new category, CR(u) (unconfirmed/uncertain),
has been defined to denote such patients, in whom remission
status is unclear. Patients in this category who have com-
pleted all initial therapy are in normal health with no clinical
evidence of Hodgkin's disease, but some radiological abnor-
mality not consistent with the effects of therapy persists at
the site of previous disease.
The recommended staging criteria, although improved, are
still imperfect. Methods for measuring nodal masses are im-
precise taking into account the difficulty in deciding whether
a nodal mass should be considered as a conglomerate mass
or multiple discrete nodes and the question of whether chains
of nodes should be measured in the transverse or longitudinal
axis. Clinical criteria for liver involvement by Hodgkin's
disease still allow considerable uncertainty and the definition
of remission status will remain imprecise without patho-
logical confirmation. Nevertheless, the Cotswolds report is to
be commended for providing up-to-date guidelines for the
initial evaluation of patients with Hodgkin's disease, taking
into account both staging and prognostic factors. This pro-
vides a standard base for patient selection for clinical trials
and inter-centre comparative studies.
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